Comparison of D2 vs D3 Lymph Node Dissection for Right Colon Cancer (RICON)

Status

Active, not recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03200834

Enrollment

239

Registered

2017-06-27

Start date

2017-01-25

Completion date

2029-01-03

Last updated

2025-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon Cancer

Keywords

Right colon cancer, D3 dissection, complete mesocolic excision, Hemicolectomy

Brief summary

Comparing different method of surgical technique D2 lymph node dissection vs D3 for right colon cancer.

Interventions

PROCEDURERight Hemicolectomy with D2 lymph node dissection

Remove right part of colon with lymph node dissection №201, №202, №211, №212 (if present), №221,№222 (Japanese classification).

PROCEDURERight Hemicolectomy with D3 lymph node dissection

Remove right part of colon with lymph node dissection №201, №202, № 203, №211, №212 (if present), №213 (if present) №221,№222, №223 (for hepatic flexure and proximal part of transverse colon cancer)(Japanese classification).

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. Agreement of the patient to participate in trial 2. Colon cancer (only adenocarcinoma ) 3. The tumor located between the cecum and the right 1/3 of transverse colon 4. Tumors T3,Т4а,b N0-2 (II-III stages) 5. Tolerance of chemotherapy 6. ECOG 0-2

Exclusion criteria

1. Patients with distant metastases 2. Tumors T1-2 (I stage) 3. Complications of tumor (perforation and full bowel obstruction) 4. Previous radiotherapy or chemotherapy 5. Synchronous or metachronous tumors 6. Women during Pregnancy or breast feeding period

Design outcomes

Primary

Measure	Time frame	Description
5-year survival	Up to 5 years post-operative	death from any cause

Secondary

Measure	Time frame	Description
morbidity	within the first 30 days after surgery	postoperative complications
mortality	within the first 30 days after surgery	death after surgery
Disease free survival 5 years after initial surgery	Up to 5 years post-operative	local and distant metastasis during 5 years after operation

Countries

Ukraine

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026